To the editor:
Do B-cell chronic lymphocytic leukemia patients with Ig V H 3-21 genes constitute a new subset of chronic lymphocytic leukemia?
With interest we read the report of Tobin et al 1 describing a new subset of B-cell chronic lymphocytic leukemia (B-CLL). After mutation analysis of rearranged immunoglobulin variable heavy chain (IgV H ) genes, they observed that B-CLL patients with somatically mutated V H 3-21 genes have an unfavorable clinical course similar to B-CLL patients with unmutated immunoglobulin genes. Their presented data and conclusions need some comments. In several studies, [1] [2] [3] as well as in our own unpublished data, a preferential usage of several V H genes is observed. Data of a selection of frequently used V H genes are summarized in Table 1 . In all studies V H 1-69 is highly represented in B-CLL and is almost exclusively unmutated. But the frequent occurrence of the V H 3-21 gene found by Tobin et al, namely in 13% of all CLL, could not be confirmed by the 3 other studies indicated (Table 1 ; studies 2-4). This discrepancy of usage of the V H 3-21 gene is statistically significant ( 2 analysis for V H 3-21 usage: studies 1 versus 2, P ϭ .013; studies 1 versus 3, P ϭ .008; studies 1 versus 4, P ϭ .020). In addition, a statistically significant difference is observed for the overall mutation frequency between studies 1 and 2 (Table 1 ; 2 analysis, P ϭ .004).
Several explanations for these different findings can be proposed: there might be a wrong annotation due to closely related germline IgV H genes. V H 3-48 is the immunoglobulin gene with the highest homology to the V H 3-21, namely, 10 basepair differences between both genes at nucleotide level; but it seems unlikely that, due to mutations at most of these positions, the germline gene is not correctly assigned. Or there might be methodologic differences between the different studies. Each of the studies inevitably excluded samples that failed on the IgV H mutation analysis, which is interesting information since this might give some insight in the sensitivity of the assays to detect clonal rearrangements. Finally, there might be a different patient population treated at each center or a particular patient group selected for IgV H sequencing.
Next to the difference in usage of the V H 3-21 gene, the relatively low mutation load observed in the somatically mutated cases described by Tobin et al is striking. Thirteen patients showed a sequence homology to the germline V H 3-21 gene between 92.8% and 98%. Ten of those show a homology between 96% and 98% (Table 1 , study 1). The threshold value of 98% to distinguish unmutated from mutated IgV H genes was originally chosen because polymorphisms, which are quite common in V H genes, can account for 2% of disparity. 4 But an alternative use of a 96% threshold is currently under debate. Kröber et al, 5 analyzing 300 In their letter Nollet et al have compared our findings with 2 prior studies on V H gene usage and their own unpublished results, and they found it remarkable that we have shown a significantly higher number of V H 3-21-utilizing CLL cases compared with the other studies. [1] [2] [3] [4] Nollet et al have speculated on the basis of the divergent results. First, they have addressed the correctness of the V H gene alignment. We have used 3 different germline databases, and it is not likely that we have aligned them incorrectly, especially since all 3 databases indicate V H 3-21 gene usage and the closest related gene, V H 3-48, displays 7-bp differences to the V H 3-21 gene. Second, Nollet et al have suggested that methodological differences could account for the disagreement between the studies. Certainly, different primer systems may have varied capability to amplify different V H genes, but we find it rather unlikely that this would explain the diverse results. Third, they have argued that the selection of patients could differ between the studies. We believe that the selection of patient material is the most probable factor explaining the different findings, since none of the referred studies are population-based. Prior studies have reported different frequencies of the mutated and unmutated subsets, and the median survival for these 2 groups has varied, thus indicating that different patient populations have been selected for V H gene analysis. [1] [2] [3] [4] [5] In addition, we cannot rule out that the difference in frequency of V H 3-21 usage compared with previous studies reflects a different genetic background or environmental factors in the Scandinavian population/ countries.
Nollet et al have also brought up the discussion about the appropriate cutoff level to distinguish mutated and unmutated CLL. We have chosen the mutation border of 98% to eliminate the possibility of polymorphic sites in accordance with previous CLL studies. [3] [4] [5] Kröber et al have recently shown that a cutoff level at 97% gave the best separation of the 2 subsets regarding overall survival. 6 Using this threshold, some of our mutated V H 3-21 cases would indeed be interpreted as unmutated. But the true biologic level that distinguishes somatically mutated V H genes from unmutated ones is currently unknown and may also differ for different V H genes. Most of our mutated V H 3-21 cases have a low frequency of mutations, but almost half of the mutations were found in hypermutation hotspot regions (RGYW/WRCY), indicating that they were introduced by the somatic hypermutation mechanism rather than representing V H 3-21 gene polymorphisms. To solve this issue, future studies are warranted to analyze the germline V H genes in cases that display a low number of somatic hypermutations and compare the germline sequence with the sequence of the clonal rearrangement.
Despite the V H gene mutation status, we still believe that the V H 3-21-utilizing cases represent an additional entity, especially since they display certain features with short and in some cases identical CDR3 structure and a highly preferential V 2-14 usage. We have now identified 24 cases with V H 3-21 usage (out of 215 analyzed CLL cases), where 17 were mutated and 7 unmutated according to the 98% cutoff level. The V H 3-21 CLL cases from our published study originated from the central and northern counties in Sweden, but we have now also found V H 3-21-utilizing CLL cases from both Finland and southern Sweden. In addition, a German research group has also identified V H 3-21-positive cases with similar genotypic findings that showed an inferior outcome irrespective of their mutational status (S. Stilgenbauer, personal communication, April 3, 2002) . But it will be important to study larger numbers of V H 3-21-positive cases to confirm our findings and to fully evaluate the prognostic impact of V H 3-21 gene usage in CLL. Additionally, multicenter and population-based studies are needed to investigate the clinical significance of V H gene usage in general in CLL. To the editor:
Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis
Most cases of hereditary hemochromatosis are due to a single nucleotide mutation in the hemochromatosis gene (HFE) that results in a Cys to Tyr conversion at amino acid 282 (Cys282Tyr) in the protein. 1 Sequencing revealed a second mutation (His63Asp) in the HFE protein, but the penetrance of this mutation is much lower compared to Cys282Tyr. Although a candidate early in the search for the hemochromatosis gene, the transferrin receptor (TFR) was not found to be mutated in hemochromatosis. Several years ago, we discovered a second human transferrin receptor termed transferrin receptor 2 (TFR2). 2 Recently, a hemochromatosis pedigree was discovered in Sicily, where a non-sense mutation at position 250 in the TFR2 gene was found. 3 Affected individuals lacked the Cys282Tyr HFE mutation. The carrier frequency of this mutation is 0.9% among a cohort of southern and central Europeans. 4 Roetto and colleagues recently reported 2 new mutations (at exon 2, 84-88insC, resulting in Glu60Xaa; and at exon 4, Met172Lys) in iron overload patients having what has been termed hemochromatosis type 3. 5 A fourth inactivating mutation of TFR2 (a 4-amino-acid loss Ala-Val-Ala-Gln at 594-597) has recently been reported. 6 Here, we investigated the genomic DNA from individuals having atypical hemochromatosis with the aim to look for a correlation between mutations of the TFR2 gene and an altered iron phenotype. We also asked whether differences in penetrance of the Cys282Tyr mutation were associated with mutations in TFR2. The study included several selected cohorts: (1) Sibling pairs homozygous for HFE Cys282Tyr with a discordant phenotype. The most common discordance between homozygote siblings was serum ferritin concentration. Many of these patients, however, also exhibited significant differences in liver fibrosis and aminotransferase levels (11 patients); (2) Non-Cys282Tyr HFE homozygotes with evidence of iron excess (7 patients), which included patients having evidence of iron overload but lacking the Cys282Tyr mutation (3 patients), a patient normal at the 282 position but homozygous for His63Asp (1 pt), and patients with iron overload but heterozygous for Cys282Tyr (3 patients); (3) Homozygous (Cys282Tyr) relatives of probands identified in a blood bank screen (because of elevated transferrin saturation) who have evidence of morbidity (3 patients); and (4) Cys282Tyr homozygotes under 30 years of age with iron overload (9 patients). In addition, we investigated samples from 10 healthy individuals as controls. Values for serum iron, transferrin saturation, and serum ferritin were available from all individuals.
Genomic DNA was analyzed by polymerase chain reactionsingle strand conformation polymorphism (PCR-SSCP) as previously described. 7 Nineteen primer pairs were designed using sequence information from the Genbank for TFR2 (GI 3135305) from the complete sequence for chromosome 7q22. Each PCR reaction contained 20 ng DNA, 10 pmol of each of the primers, 2 nmol of each of the deoxynucleoside triphosphates (dNTPs), 0.5 units Taq DNA polymerase, and 3 Ci (11.1 ϫ 10 4 Bq) ␣-[ 32 P] deoxycytidine triphosphate (dCTP) in 20 L of the specified buffer with 1.5 mM MgCl 2 . The PCR cycles were 30 seconds for denaturing at 94°C, 40 seconds for annealing at 60°C, and 60 seconds for extension at 72°C (35 cycles). The samples were separated on a 6% nondenaturating polyacrylamide mutation detection enhancement (MDE) gel. DNA purified from mutant candidate bands showing altered migration through SSCP analysis was directly sequenced by the ABI PRISM dye terminator cycle sequencing reaction (Perkin Elmer, Foster, CA).
Analysis of exon 10 of TFR2 revealed an aberrantly shifted band ( Figure 1A ) in a sample from an individual in group A, pedigrees in which a discordance existed in phenotype between Cys282Tyr homozygous sibling pairs. Direct nucleotide sequencing found a GϾA transversion at nt 1391, resulting in a substitution at codon 455 of Gln (mutant) for an Arg (normal sequence). The 
